Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth ...
These findings are important because they suggest that more selective JAK inhibition, particularly targeting JAK1 or JAK2, can effectively reduce organ pathology and pathogenic IFN-γ-producing immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results